Communiqués NexImmune, Inc.

Actions

NEXI

US65344D2080

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 20:08:50 29/12/2025			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	-.--%		-.--%	+9 900,00%

27/08/24	NexImmune, Inc. annonce la démission de Kristi Jones à titre de chef de la direction	CI
27/08/24	NexImmune, Inc. annonce des changements à la direction	CI

Communiqués

02/02/24	NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
01/12/23	Neximmune : Failure to Satisfy Listing Rule - Form 8-K	PU
24/10/23	NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	AQ
19/10/23	NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	AQ
19/10/23	NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	GL
18/10/23	NexImmune Announces 1-for-25 Reverse Stock Split	GL
18/10/23	NexImmune Announces 1-for-25 Reverse Stock Split	AQ
31/08/23	NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	GL
31/08/23	NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	AQ
10/08/23	NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates	GL
05/06/23	NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K	PU
05/06/23	NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting	AQ
22/05/23	NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting	AQ
15/05/23	NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates	GL
26/04/23	NEXIMMUNE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events (form 8-K)	AQ
26/04/23	NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting	AQ
28/03/23	NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
28/03/23	NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates	AQ
10/03/23	NEXIMMUNE, INC. : Regulation FD Disclosure (form 8-K)	AQ
16/02/23	NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR	AQ
18/01/23	NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases	AQ
08/12/22	Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain	AQ
14/11/22	NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/11/22	NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update	AQ
28/10/22	NEXIMMUNE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ